Cargando…

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report

EML4-ALK fusions are targetable oncogenic drivers in a subset of advanced non-small cell lung cancer (NSCLC) patients that can benefit from selected ALK inhibitors. Precise detection of ALK fusions may yield critical information for selection of appropriate therapy and hence improve patient survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yingying, Jia, Ran, Shao, Yang W., Zhu, Liuqing, Ou, Qiuxiang, Yu, Man, Wu, Xue, Zhang, Yanbei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411253/ https://www.ncbi.nlm.nih.gov/pubmed/32850382 http://dx.doi.org/10.3389/fonc.2020.01259

Ejemplares similares

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
por: Kleczko, Emily K., et al.
Publicado: (2023)

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
por: Hsiao, Sheng-Yen, et al.
Publicado: (2021)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
por: Sugiyama, Keiji, et al.
Publicado: (2021)

EML4-ALK rearrangement in primary malignant fibrous histiocytoma of the lung treated with alectinib: A case report
por: Zhang, Shuai, et al.
Publicado: (2022)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
por: Zhu, Lin, et al.
Publicado: (2023)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
por: Tanimoto, Azusa, et al.
Publicado: (2014)

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy
por: Reclusa, Pablo, et al.
Publicado: (2019)

EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
por: Matsuda, Hironari, et al.
Publicado: (2021)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report
por: Sun, Ning, et al.
Publicado: (2021)

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
por: Shi, Liang, et al.
Publicado: (2023)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
por: Harada, Daijiro, et al.
Publicado: (2021)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma
por: Kuribayashi, Hidehiko, et al.
Publicado: (2015)

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion
por: Yin, Qiang, et al.
Publicado: (2021)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer
por: Xiao, DeSheng, et al.
Publicado: (2016)

Bilateral breast adenocarcinomas with EML4–ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?
por: Liu, Chao, et al.
Publicado: (2016)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Phase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis
por: Qin, Zhen, et al.
Publicado: (2021)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1p9cmmo6uj92tf8sec8ovbb9dq